Categories: News

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company’s website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 10, 2024.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com

Staff

Recent Posts

Medexus Schedules First Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP)…

1 hour ago

Medtronic to announce financial results for its first quarter of fiscal year 2026

GALWAY, Ireland, Aug. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in…

1 hour ago

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased…

1 hour ago

QuidelOrtho Reports Second Quarter 2025 Financial Results

― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA…

1 hour ago

Ategenos Secures Foundational U.S. Patent for First SmartPatch Platform Targeting $1T+ Medication Non-Adherence Crisis

Only platform enabling real-time detection and intervention for medication non-adherence at community scale CAMBRIDGE, Mass.,…

1 hour ago

bioMérieux Develops Game Changing Quality Control Solution GENE-UP® PRO HRM

DNA-Based Heat Resistant Mold Test Delivers Deeper Diagnostics in a Fraction of the Time, On-Site…

1 hour ago